Celltrion looks set to be able to launch a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in the US beginning on 1 June 2025 after settling patent-litigation proceedings with the originator – although, crucially, the firm is yet to pick up US Food and Drug Administration approval for its CT-P41 denosumab candidates.
According to a consent judgment and injunction signed by a judge in a federal district court in New Jersey, Celltrion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?